Drug Trial Radar · NCT06957886
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
566
Planned (sponsor's estimate)
Start
May 15, 2025
Primary completion
May 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- First posted
- May 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a registered, phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable, locally recurrent or metastatic HER2-low breast cancer.
Conditions
- HER2-low Breast Cancer
Interventions
BL-M07D1Drug
Administration by intravenous infusion for a cycle of 3 weeks.
Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxelDrug
Oral administration of Capecitabine. Administration by intravenous infusion of Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Up to approximately 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.